CYP2D6 allelic frequencies in young-onset Parkinson's disease

Neurology

Volumn 47, Issue 1, 1996, Pages 225-230

  Sandy, M S ^a,c   Armstrong, M ^b   Tanner, C M ^a   Daly, A K ^b   Di Monte, D A ^a   Langston, J W ^a   Idle, J R ^b  

^a PARKINSON S INSTITUTE   (United States)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

^c CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ALLELE; ARTICLE; CONTROLLED STUDY; DISEASE CLASSIFICATION; GENETIC SUSCEPTIBILITY; HUMAN; MAJOR CLINICAL STUDY; ONSET AGE; PARKINSON DISEASE; PRIORITY JOURNAL; RISK FACTOR;

EID: 0030056697     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.47.1.225     Document Type: Article

References (51)

1. Barbeau A, Roy M. Etiology of Parkinson's disease: a research strategy. Can J Neurol Sci 1984;11:24-28.
2. Barbeau A, Cloutier T, Roy M, Plasse L, Paris S, Poirier J. Ecogenetics of Parkinson's disease: 4-hydroxylation of debrisoquine. Lancet 1985;2:1213-1216.
3. Smith RL, Idle JR, Mahgoub AA, Sloan TP, Lancaster R. Genetically determined defects of oxidation at carbon centres of drugs [letter]. Lancet 1978;1:943-944.
4. Barbeau A, Roy M, Cloutier RT. Smoking, cancer, and Parkinson's disease [letter]. Ann Neurol 1986;20:105-106.
5. Poirier J, Roy M, Campanella G, Cloutier T, Paris S. Debrisoquine metabolism in parkinsonian patients treated with antihistamine drugs [letter]. Lancet 1987;2:386.
6. Comella CL, Tanner CM, Goetz CG, Gans S, Rapp D, Fischer J. Debrisoquine metabolism in Parkinson's disease [abstract]. Neurology 1987;37(suppl 1):261-262.
7. Steventon GB, Heafield MTB, Waring RH, Williams RC. Xenobiotic metabolism in Parkinson's disease. Neurology 1989; 39:883-887.
8. Benitez J, Ladero JM, Jimenez-Jimenez FJ, et al. Oxidative polymorphism of debrisoquine in Parkinson's disease. J Neurol Neurosurg Psychiatry 1990;53:289-292.
9. Gudjonsson O, Sanz E, Alvan G, Aquilonius S-M, Reviriego J. Poor hydroxylator phenotypes of debrisoquine and S-mephenytoin are not overrepresented in a group of Parkinson's disease patients [letter]. Br J Clin Pharmacol 1990;30:301-302.
10. Meillard MN, Bentue-Ferrer D, Brunet-Bourgin F, Morel G, Allain H. Etude de l'hydroxylation de la debrisoquine dans la maladie de Parkinson. Presse Med 1990;19:947-949.
11. Kallio J, Marttila RJ, Rinne UK, Sonninen V, Syvalahti E. Debrisoquine oxidation in Parkinson's disease. Acta Neurol Scand 1991;83:194-197.
12. Steiger MJ, Lledo P, Quinn NP, Marsden CD, Turner P, Jenner PC. Debrisoquine hydroxylation in Parkinson's disease. Acta Neurol Scand 1992;86:159-164.
13. 450 CYP2D6 locus. Nature 1990;347:773-776.
14. Heim M, Meyer UA. Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplification. Lancet 1990; 336:529-532.
15. Daly AK, Armstrong M, Monkman SC, Idle ME, Idle JR. Genetic and metabolic criteria for the assignment of debrisoquine 4-hydroxylation (cytochrome P4502D6) phenotypes. Pharmacogenetics 1991;1:33-41.
16. Nakamura K, Goto F, Ray WA, et al. Interethnic differences in genetic polymorphism of debrisoquin hydroxylation between Japanese and Caucasian populations. Clin Pharmacol Ther 1985;38:402-408.
17. Iyun AO, Lennard MS, Tucker GT, et al. Metoprolol and debrisoquin metabolism in Nigerians: lack of evidence for polymorphic oxidation. Clin Pharmacol Ther 1986;40:387-394.
18. Lou YC, Ying L, Bertilsson L, Sjoqvist F. Low frequency of slow debrisoquine hydroxylation in a native Chinese population [letter]. Lancet 1987;2:852-853.
19. Steiner E, Bertilsson L, Sawe J, Bertling I, Sjoquist F. Polymorphic debrisoquin hydroxylation in 757 Swedish subjects. Clin Pharmacol Ther 1988;44:431-435.
20. Caporaso NE, Tucker MA, Hoover RN, et al. Lung cancer and the debrisoquine metabolic phenotype. J Natl Cancer Inst 1990;82:1264-1272.
21. Alvan G, Bechtel P, Iselius L, Gundert-Remy U. Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations. Eur J Clin Pharmacol 1990;39:533-537.
22. Armstrong M, Daly AK, Cholerton S, Bateman DN, Idle JR. Mutant debrisoquine hydroxylase genes in Parkinson's disease. Lancet 1992;339:1017-1018.
23. Smith CAD, Gough AC, Leigh PN, et al. Debrisoquine hydroxylase gene polymorphism and susceptibility to Parkinson's disease. Lancet 1992;339:1375-1377.
24. Kurth MC, Kurth JH. Variant cytochrome P450 CYP2D6 allelic frequencies in Parkinson's disease. Am J Med Genet 1993;48:166-168.
25. Kurth JH, Hubble JP, Eggers EA, Kurth MC, Koller WC, Lieberman AN. Lack of association of CYP2D6 and Mao-B alleles with Parkinson's disease in a Kansas cohort [abstract]. Neurology 1995;45(suppl 14):A429.
26. Agundez JA, Jimenez-Jimenez FJ, Luengo A, et al. Association between the oxidative polymorphism and early onset of Parkinson's disease. Clin Pharmacol Ther 1995;57:291-298.
27. Tanner CM. Parkinson's disease. In: Gorelick PB, Alter M, eds. Handbook of neuroepidemiology. New York: Marcel Dekker, 1994:253-280.
28. Langsten JW, Widner H, Goetz CG, et al. Core assessment program for intracerebral transplantations (CAPIT). Mov Disord 1992;7:2-13.
29. Blin N, Stafford DW. A general method for isolation of high molecular DNA from eukaryotes. Nucleic Acids Res 1976;3: 2303-2308.
30. Sambrook J, Fritsch EF, Maniatis T. Molecular cloning. A laboratory manual. 2d ed. Cold Spring Harbor, MA: Cold Spring Harbor Laboratory Pr, 1989.
31. Gonzalez FJ, Skoda RC, Kimura A, et al. Characterization of the common genetic defect in humans deficient in debrisoquine metabolism. Nature 1988;331:442-446.
32. Kimura S, Umeno M, Skoda RC, Meyer UA, Gonzalez FJ. The human debrisoquine 4-hydroxylase (CYP2D6) locus: sequence and identification of the polymorphic CYP2D6 gene, a related gene and a pseudogene. Am J Hum Genet 1989;45:889-905.
33. Dean AG, Dean JA, Burton AH, Dicker RC. Epi Info, Version 6: a word processing, database, and statistics program for epidemiology on microcomputers. Centers for Disease Control, Atlanta, GA, 1990.
34. Mehta CR, Patel NR, Gray R. Computing an exact confidence interval for the common odds ratio in several 2 × 2 contingency tables. J Am Stat Assoc 1985;78:969-973.
35. Steen VM, Andreassen OA, Daly AK, et al. Detection of the poor metabolizer-associated CYP2D6(D) gene deletion allele by long-PCR technology. Pharmacogenetics 1995;5:215-223.
36. Tanner CM. Epidemiology of Parkinson's disease. Neurol Clin 1992;10:317-328.
37. Fonne-Pfister R, Bargetzi MJ, Meyer UA. MPTP, the neurotoxin inducing Parkinson's disease is a potent competitive inhibitor of human and rat cytochrome P450 isozymes (P450 bufl, P450 db1) catalyzing debrisoquine 4-hydroxylation. Biochem Biophys Res Commun 1987;148:1144-1150.
38. Monks TJ, Hanzlik RP, Cohen GM, Ross D, Graham DG. Contemporary issues in toxicology. Quinone chemistry and toxicology. Toxicol Appl Pharmacol 1992;112:2-16.
39. Daly AK, Leathart JB, London SJ, Idle JR. An inactive cytochrome P450 CYP2D6 allele containing a deletion and a base substitution. Hum Genet 1995;95:337-341.
40. Evert B, Griese EU, Eichelbaum M. A missense mutation in exon 6 of the CYP2D6 gene leading to a histidine 324 to proline exchange is associated with the poor metabolizer phenotype of sparteine. Naunyn Schmiedebergs Arch Pharmacol 1994;350:434-439.
41. Saxena R, Shaw GL, Relling MV, et al. Identification of a new variant CYP2D6 allele with a single base deletion in exon 3 and its association with the poor metabolizer phenotype. Hum Mol Genet 1994;3:923-926.
42. Plante-Bordeneuve V, Davis MB, Maraganore DM, Marsden CD, Harding AE. Debrisoquine hydroxylase gene polymorphism in familial Parkinson's disease. J Neurol Neurosurg Psychiatry 1994;57:911-913.
43. Gasser T, Wszolek ZK, Trofatter J, et al. Genetic linkage studies in autosomal dominant parkinsonism: evaluation of seven candidate genes. Ann Neurol 1994;36:387-396.
44. Mazzetti P, Le Guern E, Bonnet AM, Vidailhet M, Brice A, Agid Y. Familial Parkinson's disease and polymorphism at the CYP2D6 locus [letter]. J Neurol Neurosurg Psychiatry 1994; 57:871-872.
45. Lander ES, Schork NJ. Genetic dissection of complex traits. Science 1994;265:2037-2048.
46. Nakachi K, Imai K, Hayashi S, Watanabe J, Kawajiri K. Genetic susceptibility to squamous cell carcinoma of the lung in relation to cigarette smoking dose. Cancer Res 1991;51:5177-5180.
47. Tsuneoka Y, Matsuo Y, Iwahashi K, Takeuchi H, Ichikawa Y. A novel cytochrome P-450IID6 mutant gene associated with Parkinson's disease. J Biochem 1993;114:263-266.
48. Armstrong M, Idle JR, Daly AK. A polymorphic CfoI site in exon 6 of the human cytochrome P450 CYP2D6 gene detected by polymerase chain reaction. Hum Genet 1993;91:616-617.
49. Mura C, Panserat S, Vincent-Viry M, Galteau MM, Jacqz-Aigrain E, Krishnamoorthy R. DNA haplotype dependency of debrisoquine 4-hydroxylase (CYP2D6) expression among extensive metabolizers. Hum Genet 1993;92:367-372.
50. Panserat S, Mura C, Gérard N, et al. DNA haplotype-dependent differences in the amino acid sequence of debrisoquine 4-hydroxylase (CYP2D6): evidence for two major allozymes in extensive metabolisers. Hum Genet 1994;94:401-406.
51. Johansson I, Lundqvist E, Bertilsson L, Dahl M-L, Sjöqvist F, Ingelman-Sundberg M. Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. Proc Natl Acad Sci USA 1993;90:11825-11829.